Market Cap: $159.94B
Market Cap: $159.94B

Pfizer Inc. ( PFE ) is drawing attention as the latest developments come into focus. Pfizer Inc. (PFE) is entering a critical phase as it maneuvers through the looming threats of patent expirations th…

Pfizer Inc. ( PFE ) is currently navigating a pivotal transformation, emphasizing its oncology portfolio to counterbalance impending revenue losses from patent expirations. The pharmaceutical giant fa…

Pfizer Inc. ( PFE ) is navigating a pivotal transformation centered on expanding its oncology portfolio to counterbalance the looming threats of revenue decline from patent expirations. The company's…

In an ever-evolving pharmaceutical landscape, Pfizer Inc. ( PFE ) is strategically pivoting to mitigate the impending challenges posed by patent expirations of its key blockbuster products. As the com…

Pfizer Inc. ( PFE ) is navigating a pivotal transformation as it shifts its focus towards expanding its oncology portfolio amidst imminent patent expirations and fluctuating revenue streams. Once reco…

Pfizer Inc. ( PFE ) is undergoing a transformative phase as it pivots strategically towards oncology amidst significant market challenges and revenue volatility driven by patent expirations and decrea…

Pfizer Inc. (PFE) is navigating a complex landscape shaped by patent expirations and an evolving oncology strategy aimed at stabilizing its revenue post-COVID-19. As the company faces declining sales…

Pfizer Inc. ( PFE ) continues to redefine its strategic trajectory in the face of industry challenges, particularly focusing on its oncology portfolio as a vital countermeasure against the impending p…

The looming patent expirations are certainly a pressing concern for Pfizer, with key products such as the anticoagulant Eliquis and the breast cancer medication Ibrance approaching the brink of market…

Pfizer Inc. ( PFE ) has found itself navigating a challenging landscape as it pivots from a pandemic-era focus to a strategic recovery plan aimed at long-term growth. The company, once celebrated for…

Pfizer Inc. ( PFE ) is strategically navigating a multitude of challenges that have surfaced in recent years, primarily stemming from the post-pandemic landscape. As the company looks to rebound, its…

Pfizer Inc. (Ticker: PFE) has recently secured an important approval from the U.S. FDA for its drug IBRANCE, which now includes an expanded indication for maintenance treatment in patients suffering f…

In recent developments, Pfizer Inc. (Ticker: PFE) secures a noteworthy advancement in cancer care with the FDA's approval of its Ibrance (palbociclib) regimen for frontline maintenance in metastatic b…

Pfizer is navigating significant changes in its leadership and product strategy, with the recent resignation of Chief Financial Officer Dave Denton and the appointment of Cecile Guegan as interim CFO.…
Pfizer Inc (Ticker: PFE) has made significant strides in the treatment of hemophilia with the recent expansion of the approval of its drug, HYMPAVZI (marstacimab), by the European Commission. This exp…
Pfizer Advances Lyme Disease Vaccine Despite Clinical Trial Challenges Pfizer is pushing ahead with its regulatory application for a Lyme disease vaccine candidate, even in the wake of a recent Phase…
CNBC Cures: Raising Awareness for Rare Diseases In a significant effort to illuminate the struggles of Americans living with rare diseases, CNBC has initiated "CNBC Cures," a campaign dedicated to amp…
Pfizer's Promising Advance in Prostate Cancer Treatment: TALAPRO-3 Study Results Pfizer announces important topline results from the Phase 3 TALAPRO-3 study, focusing on the combination of Talzenna (t…
Lucid Group Appoints Dr. Rod MacKenzie as New Board Chair, Reinforcing Commitment to Patient-Centric Innovations Lucid Group, a frontrunner in healthcare communications and commercialization, announce…
U.S. Court Questions Legality of Vaccine Advisory Panel Changes Amid Public Health Scrutiny A federal court has raised significant questions regarding the legality of recent changes made by the U.S. g…
Legal Accountability and Public Health Policy: A Crucial Turning Point Recent developments within the U.S. legal landscape have raised significant concerns about the government’s handling of public he…
Pfizer Positioned for a Strategic Comeback in the Biopharmaceutical Sector Pfizer is currently monitoring opportunities for a turnaround as it emerges from the tumult caused by the COVID-19 pandemic.…
BioNTech Focuses on Personalized Cancer Treatments and Strategic Collaborations BioNTech is strategically dedicated to maximizing value for patients and shareholders by harnessing its advancements in…
Entering the Next Frontier: Pfizer's Commitment to Innovative Oncology Solutions In the competitive landscape of oncology, the stakes are continually evolving, especially as pivotal clinical data emer…
Pfizer's Ecnoglutide: A New Era in Obesity Treatment in China Pfizer Inc. celebrates a significant achievement with the recent approval from China’s National Medical Products Administration for its in…
Shifts in Investor Sentiment Pose Questions for Pfizer’s Future Prospects Recent analysis reveals a notable bearish sentiment among affluent investors regarding Pfizer Inc. This shift is particularly…
Navigating Regulatory Challenges: The Future of Innovation in Pharmaceuticals In recent discussions at the CNBC Cures Summit in New York City, Congressman Jake Auchincloss raised significant concerns…
### Challenges in FDA Oversight: Implications for Innovation in Rare Disease Therapies The intersection of pharmaceutical innovation and regulatory oversight remains a contentious topic, particularly…
### Salesforce's Fourth-Quarter Performance and Its Implications for the Software Industry Salesforce's recent fourth-quarter earnings reveal a significant evolution in the enterprise software landsca…
Pfizer’s FDA Approval for BRAFTOVI Regimen Enhances Oncology Portfolio Pfizer Inc. celebrates a pivotal achievement with the full approval by the U.S. Food and Drug Administration (FDA) of its BRAFTOV…
Kyntra Bio Inc. Advances Cancer Treatment Options with FG-3246 Clinical Trial Kyntra Bio Inc. is making strides in the oncology space with its recent Phase 1b/2 clinical trial exploring the efficacy o…
Pfizer Expands Oncology Portfolio with FDA Approval of BRAFTOVI Combination for Metastatic Colorectal Cancer Pfizer Inc. achieves a significant milestone in its oncology division following the full ap…
Enforcement Credibility and Pfizer’s Compliance Risk A public debate over accountability and leadership at federal law-enforcement agencies is creating fresh uncertainty for pharmaceutical companies s…
Pfizer highlights BRAFTOVI regimen for advanced colorectal disease Oncology strategy centres on BRAF-targeted regimen Pfizer is issuing a brief update on its BRAFTOVI regimen for metastatic colorectal…
Pfizer flags BRAFTOVI update for metastatic colorectal cancer Pfizer is sharing a brief update on Tuesday about its BRAFTOVI regimen for metastatic colorectal cancer (mCRC), underscoring the company’s…
Pharma earnings flag 2026 as a make-or-break year Europe’s major drugmakers report mixed quarterly results but emphasise what comes next: 2026 is shaping up as a defining year after a turbulent 2025,…
New federal platform names Pfizer among initial suppliers Pfizer is among five drugmakers whose medicines appear in TrumpRx, a federal prescription drug platform launched on Feb. 5, 2026 that aims to…
White House rolls out TrumpRx with Pfizer on initial list, prompting industry scrutiny Main Topic — What Pfizer’s inclusion in TrumpRx means for drug pricing and access The federal TrumpRx platform, l…
Pfizer targets monthly injectable as a practical challenger in obesity market Pfizer is positioning its long-acting injectable PF′3944 as a potential game-changer in obesity treatment after releasing…
Broadcast Trading Rules Shape Pharma Narrative CNBC’s Investing Club with Jim Cramer is reinforcing how media-driven trading protocols are shaping the public narrative around large pharmaceutical comp…
Washington Funding Standoff Raises Regulatory Uncertainty for Pfizer A looming U.S. government shutdown after Congress fails to pass a funding bill is creating immediate regulatory uncertainty for pha…
Texas Investigates Financial Incentives in Pediatric Vaccination Practices Texas Attorney General Ken Paxton announces an investigation into potential financial incentives linked to the vaccination of…
Strategic Collaboration: Pfizer and Novavax Join Forces to Advance Vaccine Development In a notable development within the pharmaceutical sector, Novavax, Inc. has secured a licensing agreement with P…
Pfizer and Novavax Forge Strategic Partnership to Enhance Vaccine Development Pfizer Inc. has entered a pivotal licensing agreement with Novavax, Inc. that permits the pharmaceutical giant to utilize…
Transformative Shift in Obesity Treatment: The Rise of Oral GLP-1 Medications The obesity treatment landscape is undergoing a significant shift with the advent of oral GLP-1 medications, a development…
Transforming the Obesity Treatment Landscape: The Rise of Oral GLP-1 Medications The obesity treatment market is undergoing a notable transformation with the introduction of oral GLP-1 medications, wh…
Pharmaceutical Firms Seek Innovation Amidst Patent Expirations In a rapidly evolving biotech landscape, pharmaceutical giants like Pfizer are increasingly turning to mergers and acquisitions (M&A) to…
Pfizer Navigates the M&A Landscape Amidst Patent Expirations The biotech sector is experiencing a transformative wave of mergers and acquisitions (M&A) as pharmaceutical giants like Pfizer seek to rep…
Novo Nordisk's Strategic Shift in Weight Loss Market Amidst Competition Novo Nordisk is currently undergoing a pivotal transformation in the weight loss sector, a space it once dominated but has recen…
Pfizer Faces Rising Drug Prices Amid Industry Scrutiny Pfizer, a leading player in the pharmaceutical industry, is preparing for a significant price increase on over 350 branded medications in the Uni…